CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...